CoChat
Sign Up
Cited by 20

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

APOE-Targeted Therapeutics for Alzheimer's Disease

Yassine, Hussein N., Hugo, Cristelle, O'Donovan, Bernadette, Stephens, Isaiah O., Johnson, Lance A., Cole, Gregory, TCW, Julia, Johansson, Jan, Kisler, Kassandra, Chiba-Falek, Ornit·2025·The Journal of Neuroscience
DOI 10.1523/jneurosci.1388-25.2025PMC PMC12614056
Open this paper in CoChat — free account

Abstract

Apolipoprotein E (APOE) is the major lipid transport protein in the brain. Produced primarily by astrocytes and microglia, it delivers cholesterol and other lipids for membrane repair, synaptic maintenance, and immune regulation. Through interactions with specific lipid receptors, APOE maintains neuronal and vascular health. The APOE ε4 allele (APOE4), carried by approximately one-quarter of the population, has an altered protein conformation, which reduces lipid transport efficiency and modifies receptor binding. These changes disrupt lipid homeostasis, increase risk of chronic unresolved neuroinflammation and vascular inflammation, and cause breakdown of the blood–brain barrier (BBB), thus increasing neuronal vulnerability to disease pathology and elevating risk for Alzheimer's disease (AD). In this review, we organize the effects of APOE4 into three interconnected “hits” that modulate disease progression: disrupted lipid handling, neurovascular inflammation, and neuronal dysfunction. These interconnected hits help explain why amyloid- and tau-directed therapies alone have modest success in treating AD, particularly in APOE4 carriers. We review emerging APOE-related therapeutic strategies designed to address these mechanisms directly, including structure correctors to restore normal protein folding, agents that enhance lipidation and receptor-mediated lipid transport, approaches that modulate downstream inflammatory responses, and gene therapies aimed at isoform switching or allele silencing. By aligning therapeutic strategies with specific aspects of APOE4 biology, such approaches have the potential to provide broader and safer benefits, complement existing disease-modifying therapies, and improve outcomes for individuals at heightened genetic risk of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.1388-25.2025

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 96

  1. 10.1038/jcbfm.2014.172 · DOI
  2. Alruwais, 2022, Evidence of emerging BBB changes in mid-age apolipoprotein E epsilon-4 carriers, Brain Behav, 12, e2806, 10.1002/brb3.2806 · DOI
  3. 10.1111/nyas.14907 · DOI
  4. Azhar, 2019, Novel ABCA1 peptide agonists with antidiabetic action, Mol Cell Endocrinol, 480, 1, 10.1016/j.mce.2018.09.011 · DOI
  5. Balasubramaniam, 2024, Rescue of ApoE4-related lysosomal autophagic failure in Alzheimer’s disease by targeted small molecules, Commun Biol, 7, 60, 10.1038/s42003-024-05767-9 · DOI
  6. Balducci, 2015, The continuing failure of bexarotene in Alzheimer's disease mice, J Alzheimers Dis, 46, 471, 10.3233/JAD-150029 · DOI
  7. 10.1084/jem.20221137 · DOI · Paper page
  8. Bielicki, 2016, ABCA1 agonist peptides for the treatment of disease, Curr Opin Lipidol, 27, 40, 10.1097/MOL.0000000000000258 · DOI
  9. 10.1523/JNEUROSCI.5198-13.2014 · DOI · Paper page
  10. Bonham, 2016, The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer’s disease, Acta Neuropathol Commun, 4, 65, 10.1186/s40478-016-0339-y · DOI
  11. 10.1038/37635 · DOI
  12. 10.1194/jlr.R700014-JLR200 · DOI
  13. 10.2353/ajpath.2010.090973 · DOI · Paper page
  14. 10.1016/j.neurobiolaging.2015.10.010 · DOI
  15. 10.1016/S0306-4522(03)00361-0 · DOI
  16. Channon, 1990, A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell line RAW 264.7, J Biol Chem, 265, 5409, 10.1016/S0021-9258(19)39374-3 · DOI
  17. 10.1016/j.cell.2019.11.016 · DOI
  18. 10.1074/jbc.M111.276162 · DOI · Paper page
  19. 10.1073/pnas.0914984107 · DOI · Paper page
  20. 10.1016/j.neuron.2020.10.008 · DOI · Paper page
  21. 10.1007/s11481-015-9627-8 · DOI
  22. 10.1002/trc2.12385) · DOI · Paper page
  23. 10.1186/s13195-016-0173-2 · DOI · Paper page
  24. Dang, 2024, Effects of Probucol on plasma amyloid-beta transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial, Lipids Health Dis, 23, 410, 10.1186/s12944-024-02398-1 · DOI
  25. Denkinger, 2024, Associations between regional blood-brain barrier permeability, aging, and Alzheimer's disease biomarkers in cognitively normal older adults, PLoS One, 19, e0299764, 10.1371/journal.pone.0299764 · DOI
  26. 10.1074/jbc.271.32.19053 · DOI · Paper page
  27. Duro, 2022, Lipids and brain inflammation in APOE4-associated dementia, Curr Opin Lipidol, 33, 16, 10.1097/MOL.0000000000000801 · DOI
  28. 10.3389/fnins.2020.00742 · DOI · Paper page
  29. Ferguson, 2024, Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease, Alzheimers Dement, 20, 2632, 10.1002/alz.13703 · DOI
  30. Ghosal, 2013, The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer's disease-like pathological features, Neurodegener Dis, 12, 51, 10.1159/000341299 · DOI
  31. Ghosal, 2016, A randomized controlled study to evaluate the effect of bexarotene on amyloid-beta and apolipoprotein E metabolism in healthy subjects, Alzheimers Dement, 2, 110
  32. 10.1002/ana.25172 · DOI
  33. Guptill, 2017, Phase 1 randomized, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics of a single escalating dose and repeated doses of CN-105 in healthy adult subjects, J Clin Pharmacol, 57, 770, 10.1002/jcph.853 · DOI
  34. 10.1096/fj.201901369RR · DOI
  35. Hashemiaghdam, 2020, Microglia heterogeneity and neurodegeneration: the emerging paradigm of the role of immunity in Alzheimer's disease, J Neuroimmunol, 341, 577185, 10.1016/j.jneuroim.2020.577185 · DOI
  36. 10.15252/emmm.201505846 · DOI · Paper page
  37. 10.1038/s41588-022-01208-7 · DOI · Paper page
  38. Hu, 2020, Simple and fast assay for apolipoprotein E phenotyping and glycotyping: discovering isoform-specific glycosylation in plasma and cerebrospinal fluid, J Alzheimers Dis, 76, 883, 10.3233/JAD-200203 · DOI
  39. 10.1089/ars.2024.0794 · DOI
  40. 10.1038/jcbfm.2013.76 · DOI · Paper page
  41. 10.1016/j.neuron.2017.11.014 · DOI · Paper page
  42. 10.1016/j.neubiorev.2024.105867 · DOI
  43. 10.1016/j.tins.2020.10.003 · DOI
  44. Kantor, 2023, Fibrin-targeting immunotherapy for dementia, J Prev Alzheimers Dis, 10, 647, 10.14283/jpad.2023.105 · DOI · Paper page
  45. Kantor B , Odonovan B , Rittiner J , Hodgson D , Lindner N , Guerrero S , Dong W , Zhang A , Chiba-Falek O (2024a) All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders. bioRxiv. · DOI
  46. 10.1038/s41467-024-50515-6 · DOI
  47. 10.1038/nrn.2017.48 · DOI · Paper page
  48. 10.1038/s41467-018-06301-2 · DOI · Paper page
  49. Krishnamurthy, 2020, Apoe mimetic improves pathology and memory in a model of Alzheimer's disease, Brain Res, 1733, 146685, 10.1016/j.brainres.2020.146685 · DOI · Paper page
  50. 10.1186/1750-1326-8-18 · DOI · Paper page
  51. 10.1038/s41593-020-00764-7 · DOI · Paper page
  52. Lexeo Therapeutics (2024) Lexeo therapeutics announces positive interim data for LX1001, first-ever gene therapy to impact the underlying genetic cause of APOE4-associated Alzheimer’s disease, at the clinical trials on Alzheimer’s disease (CTAD) conference.
  53. Li B , Wang S , Kerman B , Hugo C , Shwab EK , Shu C , Chiba-Falek O , Arvanitakis Z , Yassine HN (2025) Microglial states are susceptible to senescence and cholesterol dysregulation in Alzheimer's disease. Aging Cell e70189 [Online ahead of print]. https://doi.org/10.1111/acel.70189 · DOI
  54. Li, 2019, cPLA2 activation contributes to lysosomal defects leading to impairment of autophagy after spinal cord injury, Cell Death Dis, 10, 531, 10.1038/s41419-019-1764-1 · DOI
  55. Luz, 2016, An anti-apoE4 specific monoclonal antibody counteracts the pathological effects of apoE4 in vivo, Curr Alzheimer Res, 13, 918, 10.2174/1567205013666160404120817 · DOI · Paper page
  56. 10.1016/j.nbd.2022.105615 · DOI · Paper page
  57. 10.1038/s41586-019-1195-2 · DOI · Paper page
  58. Meier, 2025, An efficient, non-viral arrayed CRISPR screening platform for iPSC-derived myeloid and microglia models, Stem Cell Reports, 20, 102420, 10.1016/j.stemcr.2025.102420 · DOI
  59. 10.1186/s13195-023-01239-0 · DOI
  60. 10.1177/0271678X20952012 · DOI
  61. 10.1038/s41593-022-01222-2 · DOI · Paper page
  62. Nedelkov, 2025, Increased cerebrospinal fluid and plasma apoE glycosylation is associated with reduced levels of Alzheimer’s disease biomarkers, Alzheimers Res Ther, 17, 151, 10.1186/s13195-025-01795-7 · DOI
  63. 10.1002/glia.21004 · DOI
  64. 10.1074/jbc.M111.225532 · DOI · Paper page
  65. 10.1016/j.jalz.2015.04.006 · DOI · Paper page
  66. Noveir, 2022, Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys, Alzheimers Res Ther, 14, 87, 10.1186/s13195-022-01028-1 · DOI
  67. O'Hare, 2016, Lack of support for bexarotene as a treatment for Alzheimer's disease, Neuropharmacology, 100, 124, 10.1016/j.neuropharm.2015.04.020 · DOI
  68. 10.1038/s41580-018-0085-z · DOI · Paper page
  69. 10.3389/fncel.2014.00380 · DOI
  70. 10.1042/bj3180797 · DOI
  71. Qiao, 2024, Apoe mimic peptide COG1410 reduces Abeta deposition and improves cognitive function by inducing the transformation of A1/A2 reactive astrocytes and increasing the BDNF concentration in brain of APP/PS1 double transgenic mice, Neuroscience, 537, 116, 10.1016/j.neuroscience.2023.11.023 · DOI
  72. Rust, 2025, The blood-brain barrier as a treatment target for neurodegenerative disorders, Expert Opin Drug Deliv, 22, 673, 10.1080/17425247.2025.2480654 · DOI
  73. Rust, 2025, The blood-brain barrier: a help and a hindrance, Brain, 148, 2262, 10.1093/brain/awaf068 · DOI
  74. Sadybekov AV , et al. (2025) Development of potent, selective cPLA2 inhibitors for targeting neuroinflammation in Alzheimer’s disease and other neurodegenerative disorders. bioRxiv:2025.2003.2009.641748. · DOI
  75. 10.1016/j.expneurol.2011.11.036 · DOI
  76. 10.1016/S0140-6736(15)01124-1 · DOI · Paper page
  77. 10.1074/jbc.270.51.30749 · DOI
  78. 10.1212/WNL.0000000000008081 · DOI · Paper page
  79. Shvetcov, 2025, APOE ε4 carriers share immune-related proteomic changes across neurodegenerative diseases, Nat Med, 31, 2590, 10.1038/s41591-025-03835-z · DOI · Paper page
  80. Sin, 2023, Anti-amyloid therapy, AD, and ARIA: untangling the role of CAA, J Clin Med, 12, 6792, 10.3390/jcm12216792 · DOI
  81. 10.1038/s41593-023-01334-3 · DOI
  82. 10.1016/j.cell.2023.08.037 · DOI · Paper page
  83. 10.1038/s41593-018-0234-x · DOI · Paper page
  84. Tiwari, 2025, Lipid metabolism and neuroinflammation: what is the link?, J Exp Med, 222, e20241232, 10.1084/jem.20241232 · DOI
  85. Van Valkenburgh, 2021, Understanding the exchange of systemic HDL particles into the brain and vascular cells has diagnostic and therapeutic implications for neurodegenerative diseases, Front Physiol, 12, 700847, 10.3389/fphys.2021.700847 · DOI
  86. 10.1159/000334914 · DOI
  87. 10.1186/s13024-022-00577-1 · DOI · Paper page
  88. 10.1186/s13024-022-00549-5 · DOI
  89. Wang, 2025, Cellular senescence induced by cholesterol accumulation is mediated by lysosomal ABCA1 in APOE4 and AD, Mol Neurodegener, 20, 15, 10.1186/s13024-025-00802-7 · DOI
  90. Weisgraber, 1982, Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site, J Biol Chem, 257, 2518, 10.1016/S0021-9258(18)34954-8 · DOI · Paper page
  91. 10.1016/j.tins.2023.11.010 · DOI
  92. 10.1073/pnas.0508693102 · DOI · Paper page
  93. 10.1111/febs.16344 · DOI · Paper page
  94. Zhang, 2025, Lipid droplets in the nervous system: involvement in cell metabolic homeostasis, Neural Regen Res, 20, 740, 10.4103/NRR.NRR-D-23-01401 · DOI
  95. 10.1016/j.neurobiolaging.2016.04.020 · DOI · Paper page
  96. Zhao, 2023, Brain lipids and lipid droplet dysregulation in Alzheimer's disease and neuropsychiatric disorders, Complex Psychiatry, 9, 154, 10.1159/000535131 · DOI · Paper page

Cited by

Sorted by citations

See all 20

Metadata

Authors
Yassine, H. N., Hugo, C., O'Donovan, B., Stephens, I. O., Johnson, L. A., Cole, G., TCW, J., Johansson, J., Kisler, K., & Chiba-Falek, O.
Venue
The Journal of Neuroscience
Publisher
Society for Neuroscience
Published
2025-11-12
Volume
45
Issue
46
Pages
e1388252025
ISSN
  • 0270-6474
  • 1529-2401
DOI
10.1523/jneurosci.1388-25.2025
PMC
PMC12614056
Cited by
20
References
42
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review